So that’s that. Garry, do you want to talk a little bit about specifically gavo-cel focus and signals there?
Garry Menzel: Yes. It’s a good question, Jonathan. Good to hear your voice. Basically, with gavo-cel, what we have been advised is that if we can maintain the objective response rate that we showed in Phase I, which, if you recall, was around 30% and demonstrate durability that is a positive outcome. What’s durability? It’s basically being able to get responses that last 6 months or more, and then feeds ultimately into overall survival since that’s what the patient cares about more than anything else. We’re obviously employing checkpoint inhibitors in order to help with that from the Phase I and re-dosing strategies, as well as moving to earlier lines of therapy. There will be some translational data presented in the middle of the year.
We haven’t decided exactly at which conference, but we’ll present that in the middle of the year. And the goal, as I said, is to be able to showcase the checkpoint inhibitors are indeed helping us with durability. But that’s the readout that we’re looking for at the end of the year.
Adrian Rawcliffe: And then – thanks, Garry. And then on to your last question, the request for increased granularity on the cash flow. The short answer is, we can’t give increased granularity at this point in time, as I referred to previously. However, maybe I could say a couple of things that might be useful as you think about the modeling. I think the first is that both companies have executed a fairly significant downsizing. So the 2023 spend looks nothing like the 2022 spend for both companies. That’s the first point. Second point, the financing – the profile of financing for Adaptimmune specifically, as we’ve talked about before, is historically, and we anticipate being in the future, quite lumpy. Specifically, we tend to spend the majority of the net cash burn in the first part of the year.
And that is then — our burn is then offset by both tax credits and payments from partners that we typically receive in the second half of the year. And so the combination of that makes the cash flow through the year quite spiking. So when we put all of this together and make reasonable assumptions about the levels of efficiency going forward, we believe that we are financed into 2026 with this combined portfolio, delivering the catalysts that we have outlined previously.
Jonathan Chang: Got it. Thank you.
Operator: Our next question comes from Asthika Goonewardene of Truist Securities. Please go ahead.
Asthika Goonewardene: Hey, guys. Thanks for taking my question. All right. I get it. I know what’s going on here. Just a few quicks. The first is secret profitability to take over cell therapy, isn’t it?
Adrian Rawcliffe: Absolutely.
Asthika Goonewardene: Okay. On a serious note, Ad and Garry, okay. So a question I’d like for both of you to answer independently is from a scientific standpoint, what technologies are being brought together from both your companies that you are most interested in putting into a single cell. And then a question on using the manufacturing capacity, when do you get to use the – sorry, when the TCR2 – once the drug gets used to Adaptimmune’s manufacturing capacity? And related to that, does the merger enclosing in the second quarter allow you to build more capacity to treat lung cancer patients with gavo-cel rather than approach it on opportunistically how you outlined earlier ala, you’ll treat a lung cancer patient if there’s no ovarian cancer slots being used?
